Medication info

Nariozenta Duo Tablet 2.5/500 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Pamgen Science Co., Ltd.
Appearance
Bright yellow, double-convex, oval film-coated tablet
Packaging
60 tablets/Alu-Alu [60 tablets (10 tablets/Alu-Alu x 6)]
Approval status
Active

MFDS item code 202201810 · Approved 2022.05.03

Summary

Main use
Improves glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take the same doses of linagliptin and metformin they had been taking as the initial dose. 3. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered in combination with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with another oral antihyperglycemic drug. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do Not Administer to the Following Patients).

Ingredients

Manufacturer
Pamgen Science Co., Ltd.

Efficacy & effects

Improves glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar in patients with type 2 diabetes by using Linaagliptin and Metformin together. When used in conjunction with dietary and exercise therapies, it can effectively manage blood sugar levels. Good blood sugar control can also help in preventing complications. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take the same doses of linagliptin and metformin they had been taking as the initial dose. 3. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered in combination with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with another oral antihyperglycemic drug. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do Not Administer to the Following Patients).

Precautions

This medication can cause a rare but serious side effect known as lactic acidosis, and should not be used in patients with impaired kidney function or those with problems related to the heart or liver. It should not be administered to patients who have allergies to any of the ingredients, or those with type 1 diabetes, acute infections, severe dehydration, or certain conditions like acute myocardial infarction. Due to the risk of hypoglycemia, blood sugar changes should be carefully monitored when taken with insulin or sulfonylureas, and insulin or sulfonylurea doses may need to be adjusted as necessary. Elderly patients with declining kidney function should have regular kidney function tests, and this medication should not be used if kidney function falls below certain criteria. If undergoing radiological iodine contrast examination, this medication should be discontinued for a certain period before and after the examination, and should be resumed only after kidney function stabilizes. Patients due for surgery should discontinue this medication 48 hours before the procedure and should not resume until kidney function returns to normal post-operation. If there is suspicion of acute pancreatitis or bullous pemphigoid, this medication should be discontinued immediately and consulted with a physician. Vitamin B12 levels may drop during treatment, so those on long-term therapy should check vitamin B12 levels regularly and supplement if deficient. Women who are pregnant or may become pregnant, as well as breastfeeding mothers should not use this medication; those planning to become pregnant should consult a physician for appropriate treatments. It is recommended not to use this medication in children under 10 years of age as safety and efficacy have not been established. There may be interactions with other medications during use, so any other medications being taken must be disclosed to a physician or pharmacist. In case of overdose, serious side effects such as lactic acidosis may occur, and immediate medical attention is required, which might include procedures like hemodialysis if necessary. This medication should be stored out of the reach of children, kept dry, and should not be transferred to other containers.

Side effects

Lactic acidosis, hypoglycemia, taste disturbance, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular dermatosis, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficiency of vitamin B12, cheilitis, stomatitis, epigastric pain, dyspepsia, gastrointestinal disorders, gastritis, gastroesophageal reflux disease, colitis, bowel obstruction, tooth loss, hemorrhoids, lower abdominal pain, gastric ulcer, abdominal discomfort, constipation, upper respiratory infection, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, cerebral infarction, speech difficulties, Alzheimer's dementia, drowsiness, fatigue, chest discomfort, weakness, pain, nosebleed, oropharyngeal pain, voice disturbances, dyspnea, wet cough, rhinorrhea, asthma, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased triglycerides in the blood, increased urinary albumin/creatinine ratio, positive urinary leukocytes, decreased hemoglobin, increased potassium in the blood, increased creatinine in the blood, increased creatine phosphokinase, increased ALT, androgenetic alopecia, hyperhidrosis, hair loss, skin lesions, dermatitis, anxiety, mood disorders, insomnia, depression, contusion, bone contusion, concussion, meniscus injury, ankle fracture, hand fracture, pneumoconiosis, laceration, congestive heart failure, angina, acute myocardial infarction, palpitations, unstable angina, cardiac arrest, diabetic retinopathy, dry eye, glaucoma, cataract, eye discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, acute cholangitis, acute cholecystitis, cholangitis, cholelithiasis, hearing loss, dizziness, erectile dysfunction, goiter, kidney transplant failure, anemia, vertigo, sensory loss, osteoarthritis, limb pain, pruritus, hypertension, benign prostatic hyperplasia, angina, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, gingivitis, dyspepsia, anal bleeding, cheilitis, dental caries, enteritis, gastritis, confusional state, nocturia, dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, ideally at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Bright yellow, double-convex, oval film-coated tablet

Package unit

60 tablets/Alu-Alu [60 tablets (10 tablets/Alu-Alu x 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.